ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / RVTY / news
AVTR (56) BIO (62) MTD (78) TXG (59) ⌘ Pro Terminal →

Why RVTY Stock dropped -3.44% Today — RQD Quant Desk Flash

$151.60 -3.44% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $150.37

Revvity Inc. (RVTY) carries a Roarable Rating of C (Hold) with 65/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $17.52B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RVTY Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RVTY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Revvity Inc. (NYSE: RVTY) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $151.60 (-3.44% 1D, market cap $17.52B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, RVTY ranks #114 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RVTY compare to AVTR and BIO in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), RVTY carries a Roarable C (65/100 RQD), trailing P/E of 76.7x, gross margin of —, and ROIC of 3.1%. By comparison, AVTR (Avantor Inc.) holds a D+ grade (56/100 RQD, P/E N/A, ROIC -2.1%, cap $10.88B) and BIO (Bio-Rad Laboratories Inc.) posts a C grade (62/100 RQD, P/E 13.5x, ROIC 0.5%, cap $9.95B). Among the 5-stock peer group, BIO leads on earnings multiple (13.5x) while MTD leads on capital efficiency (30.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RVTY?
▼

Per RVTY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-28, CIK 0000031791), Revvity Inc. generated $2.86B in revenue (+3.7% YoY), $241.2M in net income, and $509.4M in free cash flow against $12.17B in total assets and $2.63B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $150.37 (-0.81%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 17.8% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 65/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.3% avg 90D alpha vs SPY • 55.6% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C
025507510065
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw C · Rk B-
Cash (12)Whales (16)SEC (16)Macro (12)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE+3.2% Base Target
$185 Bull$156 Base$122 Bear
📬 FREE RVTY RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RVTY)Realized 20D OHLCV Swing Band: ±7.2%
Deterministic 5-Pillar Attribution (65/100 Composite)
🔍 WHY RVTY SCORES 65/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (25% of score)

20D Institutional Volume Accumulation (±7.2% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (25% of score)

Altman Z-Score 3.37 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
73
Grade B$152.12+3% Next Q
Q2 (-2Q)
70
Grade B$156.61+5.6% Next Q
Q3 (-1Q)
68
Grade B-$165.33-8.3% Next Q
Current
65
Grade C$151.60+1.3% Hist 90D α
Trajectory: B (73) → C (65)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the RVTY Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 65/100 (C) score, RVTY faces multiple-compression risk if 76.7x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Priced at 77x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($146.80) or 200D SMA ($112.63) invalidates the momentum regime and cuts Target Base ($156.38) toward Bear Floor ($121.98).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RVTY• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RVTY Beats Next Quarter EPS Consensus (Dec 27, 2026) & Holds Above 200D SMA”
YES 65%NO 35%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why RVTY Stock dropped -3.44% Today — RQD Quant Desk Flash

Revvity Inc. (RVTY) dropped -3.44% to $151.60, trading at 80% of its 52-week range ($81.22 – $169.06). Solid steady margins (3% return on capital), mixed timing at 77x P/E—hold if owned, no rush to chase.

  • ▸Technical Tape: Trading at 80% of its 52-week range ($81.22 – $169.06) with RSI-14 at 51.9 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±7.2% around $151.60 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable C (Hold) backed by 52% gross margin and $509.4M annual free cash flow.
Live RVTY Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (RVTY Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
RVTY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +75.24%▲ ASCENDING CHANNEL
2026-11-03O $165.8H $165.8L $151.6C $151.6VOL 3.18M
RES: $180.7SUP: $141.0SMA50: $146.8SMA200: $112.6
$174.9$150.7$126.5$102.3$78.10RES $180.7SUP $141.0$151.62026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RVTY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RVTY Butterfly Map → + Track RVTY →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
48.0%/yr Implied 5Y Growth

vs. +3.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on RVTY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RVTY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RVTY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RVTY)

Health Care Rank #114 of 1015 ⚔️ AVTR vs RVTY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RVTY vs. AVTR, BIO, MTD, TXG)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Revvity Inc. (RVTY) ranks #114 by composite RQD confidence (65/100, grade C) and #73 by equity capitalization ($17.52B). Within this direct 5-issuer industry benchmark cohort, BIO leads on earnings valuation at 13.5x trailing P/E, while MTD leads on capital efficiency and profitability with 30.4% ROIC and 59.4% gross margin. MTD currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with RVTY at 65/100 (C).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
RVTY ACTIVE
Revvity Inc.
C 65/100 76.7x — 3.1% -3.44% $17.52B Benchmark Subject
AVTR
Avantor Inc.
D+ 56/100 — 32.7% -2.1% -2.74% $10.88B /avtr-vs-rvty →
BIO
Bio-Rad Laboratories Inc.
C 62/100 13.5x 51.9% 0.5% -1.62% $9.95B /bio-vs-rvty →
MTD
Mettler-Toledo International Inc.
B+ 78/100 39.6x 59.4% 30.4% +0.20% $33.56B /mtd-vs-rvty →
TXG
10x Genomics Inc.
C- 59/100 — 69.1% -5.7% -12.09% $9.13B /txg-vs-rvty →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-28 • CIK 0000031791 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-28), Revvity Inc. (RVTY) reported GAAP revenue of $2.86B (+3.7% vs. FY2024 revenue of $2.76B , and +3.8% cumulative change since FY2023) , GAAP net income of $241.2M, operating cash flow of $582.9M, and free cash flow of $509.4M (-6.0% YoY). On the balance sheet, RVTY closed FY2025 with $12.17B in total assets against $2.63B in total debt (Altman Z-Score: 3.37, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-28 $2.86B $241.2M $582.9M $509.4M $12.17B $2.63B
FY2024 (FY) 2024-12-29 $2.76B $270.4M $628.3M $541.7M $12.39B $3.15B
FY2023 (FY) 2023-12-31 $2.75B $693.1M $91.3M -$32.5M $10.17B $2.38B

3. RVTY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RVTY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Revvity Inc. (NYSE: RVTY) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $151.60 (-3.44% 1D, market cap $17.52B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, RVTY ranks #114 in composite RQD confidence.

How does RVTY compare to AVTR and BIO in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), RVTY carries a Roarable C (65/100 RQD), trailing P/E of 76.7x, gross margin of —, and ROIC of 3.1%. By comparison, AVTR (Avantor Inc.) holds a D+ grade (56/100 RQD, P/E N/A, ROIC -2.1%, cap $10.88B) and BIO (Bio-Rad Laboratories Inc.) posts a C grade (62/100 RQD, P/E 13.5x, ROIC 0.5%, cap $9.95B). Among the 5-stock peer group, BIO leads on earnings multiple (13.5x) while MTD leads on capital efficiency (30.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RVTY?

Per RVTY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-28, CIK 0000031791), Revvity Inc. generated $2.86B in revenue (+3.7% YoY), $241.2M in net income, and $509.4M in free cash flow against $12.17B in total assets and $2.63B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RVTY trading relative to its 50-day, 200-day, and 52-week technical levels?

RVTY last traded at $151.60 (-3.44% on volume of 2,798,703 shares), positioning the stock +3.27% above its 50-day simple moving average ($146.80) and +34.60% above its 200-day simple moving average ($112.63). Across its 52-week range of $81.22 to $169.06, RVTY sits at the 80.1% percentile with a 14-day RSI of 51.9 (NEUTRAL RANGE) and an implied next-earnings move of ±7.2% ($140.68 to $162.52).

Direct Sub-Reports: RVTY RQD Cockpit RVTY 12M Forecast RVTY Earnings & Move RVTY Dividends & DRIP RVTY Insiders & 13F RVTY Whale Options RVTY Profit Sankey RVTY News & Why
ROARABLE RATING BRIEF • RQD 65/100 (C) ✓ SEC XBRL & RQD VERIFIED

RVTY — Revvity Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-28

1. Roarable Rating Brief: What This Means to a Prospective Investor

Revvity Inc. (RVTY) earns a live Roarable RQD composite score of 65/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $151.60 (-3.44% 1D, market capitalization $17.52B).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of 3.1%, gross margin of —, operating margin of 12.5%, and free cash flow yield of 2.75%.
  • Whale 13F & Options Flow (16/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (12/20) + Forensic Balance Sheet (16/20): Incorporates a 0.95x equity beta, Altman Z-Score of 3.37, Piotroski F-Score of 7/9, and Debt/Equity of 0.36x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Revvity Inc. (RVTY) is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Laboratory Analytical Instruments industry..5B. — for further business detail.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-28), Revvity Inc. (RVTY) reported $2.86B in annual revenue (up from $2.76B in FY2024, +3.7% YoY) and $241.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.75B revenue, $693.1M net income) through FY2025, RVTY scaled operating cash flow to $582.9M and free cash flow to $509.4M, backed by $12.17B in total assets against $2.63B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C • RQD 65/100): Big institutional funds and options desks are actively positioning on the bullish side. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $81.22 – $169.06 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 76.7x trailing P/E and 48.2x EV/EBITDA against 12.5% operating margins and a 0.95x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the provided material.

  • Key Question #1: Can RVTY sustain or expand its 12.5% operating margin and 3.1% ROIC against Biotechnology: Laboratory Analytical Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $2.86B and free cash flow of $509.4M, how will capital allocation balance growth reinvestment against $2.63B in total debt?
  • Key Question #3: How sensitive is RVTY's 71.3x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.95x)?

RVTY Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Revvity Inc. (RVTY) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RVTY Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RVTY Bull vs. Bear Conversation Board — What's Your Call at $151.60?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RVTY 🐻 33% BEARISH CONVICTION
1. Pick Your Side on RVTY:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $189.97 (+21.0%)
📌 Pinned Debate

Institutional whale flow scores 19/20 and the forensic balance sheet scores 16/20, with Altman Z at 3.37 and Piotroski F at 7/9.

Institutional whale flow scores 19/20 and the forensic balance sheet scores 16/20, with Altman Z at 3.37 and Piotroski F at 7/9.. When you look under the hood at RVTY, Fundamental Cash Engine is 12/20 with 0.0% gross margins and 3.1% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (16/20) has been quietly accumulating below $169.06. My 12M target is $189.97.

SectorRotator 🐂 BULL

@SiliconVal_Bull Agree on the RQD 65/100 quality, though with 0.95 beta I'm scaling in with half-size at $157.00 and keeping dry powder in case we test $146.01.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $125.60 (-20.0%)
Spot @ $157.00

Trailing P/E of 76.7 and EV/EBITDA of 48.2 sit against a 3.1% ROIC and 2.75% FCF yield, with insider conviction scoring only 9/20.

Trailing P/E of 76.7 and EV/EBITDA of 48.2 sit against a 3.1% ROIC and 2.75% FCF yield, with insider conviction scoring only 9/20.. Look at the math on RVTY: paying 76.7x trailing P/E for 3.1% ROIC and 12.5% operating margins leaves zero margin of safety if Biotechnology: Laboratory Analytical Instruments demand softens. I'd wait for a retest of $138.16 before getting long.

LIVE TAPE